Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion
The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio.
/ 3 items
#CRNX↓
Wall Street Turns Bullish on Crinetics and Fulcrum Therapeutics
Goldman Sachs and JPMorgan highlight new clinical data that strengthen the outlook for Crinetics and Fulcrum Therapeutics, citing clearer paths to success and upside potential.
Crinetics Acromegaly Drug Approval Drives Stock Surge
Crinetics' stock surged after the FDA approved Palsonify, their once-daily oral drug for acromegaly. This rare disorder results in too much growth hormone. Palsonify is the first oral option, offering rapid, consistent control and reduced symptoms. It will be available in early October.